Main conclusions
Empagliflozin decreased cardiovascular death or heart failure hospitalisation risk across the range of baseline health status. Empagliflozin improved health status across various domains, and this benefit was sustained during long-term follow-up.
Type of Study
Complementary analysis - aimed to evaluate whether the benefits of empagliflozin varied by baseline health status assessed by the Kansas City Cardiomyopathy Questionnaires-clinical summary score and how empagliflozin impacted patient-reported outcomes - of the EMPEROR-Reduced trial, a randomised, double-blind, placebo-controlled, trial that enrolled 3730 patients whith chronic HF and a left ventricular ejection fraction ≤40%.
Importance for clinical practice
Patiens with HEFrEF should be treated with medications for improving outcome but also for improving the quality of life : empagliflozin showed benefits in both endpoints.
Our mission: To reduce the burden of cardiovascular disease.